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Introduction
Acute inflammation is a protective reaction of the body 
to infection, traumatic, postischemic, toxic, autoimmune and 
other affection. Its main goal is the localization of this process 
with the further restoration of the damaged tissue structure 
and its function [3]. In the treatment of inflammation, the 
action of widely used non-steroidal anti-inflammatory drugs 
(NSAIDs) is directed mainly to inhibit the synthesis of pro-
inflammatory mediators, cell migration and proliferation, as 
well as to stimulate the formation of anti-inflammatory agents. 
These effects allow to quickly and significantly limit the severe 
symptoms of acute inflammation and pain. However, at the 
same time, NSAIDs suppress the sanogenetic mechanism of 
inflammation. Absence of correction of pathogenetic mecha-
nisms of inflammation can lead to chronic inflammation and 
development of its complications (cicatricial changes, adhe-
sions, contractures, etc.). Also, nonselectivity of NSAIDs con-
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reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic 
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tributes to the development of known side effects. And in-
hibitors of cyclooxygenase 2, as it became known, with excess 
daily therapeutic dose also cause serious side effects [1].
New possibilities for solving this problem have already 
been demonstrated by the bioregulatory approach and the 
complex bioregulatory medicines (BRMs) created on its prin-
ciples. Old name – antihomotoxic medications (AHTM). 
Their peculiarity is the effect of ultra-small doses of compo-
nents of vegetable and mineral origin that contribute to the 
activation of detoxification and the restoration of self-regu-
lation processes, including in relation to the course of the in-
flammatory process.
Therewith, they do not suppress the natural protective and 
detoxifying mechanisms of the body [3, 9, 10, 17].
Among the BRMs, the BRM Traumeel S (injectable solu-
tion, ointment) showed great opportunities in the therapy of 
inflammatory diseases [2, 9–11, 13, 14].
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Main pharmacological actions of Traumeel S: anti-inflam-
matory (not suppression of inflammation, but its optimiza-
tion only), antiexudative, regenerating, analgesic, immuno-
correcting. These properties are provided by 14 components 
of plant and mineral origin in ultra-small (homeopathic) 
doses (fig. 1).
The effectiveness of Traumeel S in inflammatory diseases 
is confirmed by many clinical studies conducted in Germany, 
Ukraine and other countries [1–17].
Traumeel S in diseases of ENT organs
Traumeel S has proven itself in the complex therapy of 
rhinosinusitis, otitis, tonsillitis, nasopharyngitis, both in their 
independent treatment and associated with the acute respi-
ratory viral infection (ARVI), in the prevention of bacterial 
complications of ARVI [1-5, 7, 8, 12, 13].
Peresadin N.A. and Dyachenko T. of the Lugansk State 
Medical University compared the indicators of cellular and 
humoral immunity in children with the prescription of con-
ventional treatment and therapy of BRM / AHTM. It was con-
cluded that Traumeel S, in combination with other BRMs has, 
when used step-by-step, a clinically beneficial effect: the num-
ber of episodes of ARVI decreased 1.5-2 times, the manifesta-
tions of intoxication, headache and fever decreased; they were 
significantly less expressed compared with the cough control 
group, running nose, chest pain, sore throat. The course use of 
BRMs outside the aggravation period for 1-4 years indicates 
the potentiating and protective adaptation action of Traumeel 
S and other AHTMs [5, 11, 12].
Specialists from Belarus (Nikolaev V. V., Sakovich A. R., 
1999) investigated the use of complex AHTMs in the treat-
ment of acute purulent sinusitis.
The results of treatment of patients with sinusitis using the 
complex of BRMs (Traumeel S, etc.) and treated with classi-
cal therapy (antibiotics, antihistamines, vasoconstrictors, vi-
tamins) were compared. The study shows that the treatment 
scheme for acute purulent maxillary sinusitis using BRMs is 
not inferior in effectiveness to conventional treatment. At the 
same time, a faster regression of the thermosymmetry indict-
ors of the nasal mucosa, normalization of the pH of the nasal 
secretion associated with the decrease in the number of punc-
tures in the group of patients receiving BMRs, indicates its 
undeniable advantages [15].
Traumeel S in pulmonology
Polish colleagues demonstrated that the use of a single 
Traumeel S ampoule once a week in patients with corticoste-
roid-dependent bronchial asthma allows lowering the daily 
dose of corticosteroids (triamcinolone) after five months 
from 4.6 to 2.6 mg, and in some patients even give up it.
It is noted that the use of Traumeel S leads to an improve-
ment in the overall clinical condition of patients, an increase 
in muscle strength, and also contributes to the reduction of 
complications associated with prolonged corticosteroid the-
rapy [11].
Traumeel S in nephrologic diseases
In the campus of Uzhhorod State University (Kovalchuk 
I.A. et al., 1999), the efficacy of BMRs in the treatment of pa-
tients with chronic pyelonephritis - Traumeel S, etc. was stud-
ied. In the main group, the BMR was used along with etio-
tropic drugs (antibiotics). As control was an identical group 
of patients who received treatment according to the standard 
method with allopathic drugs only. In patients of the main 
group, subjective improvement of the condition occurred 
much earlier, the laboratory indicators were faster than in the 
control group.
No signs of toxicity, intolerance, side effects of use of 
AHTM were observed [16].
Traumeel S, practical recommendations
The most informative indicator describing the presence 
and intensity of the inflammatory process is the concentra-
tion of the C-reactive protein (CRP) of blood serum. The in-
crease in the level of CRP up to 3-7 mg / l already indicates 
local inflammation and serves as a criterion for the prescrip-
tion of BMR Traumeel S. The criterion for stopping to receive 
Traumeel S is a decrease in the level of CRP below 3 mg / l 
[6].
The studies showed there has been an increase in the ef-
fectiveness of therapy for inflammation with the combina-
tion of BMR Traumeel S injections with the local (ointment) 
form. During the acute period, along with the course of in-
jections, it is recommended to apply locally ointment [2, 13, 
14] (table 1).
Table 1
Recommendations for the dosage of Traumeel S when combined 
with several dosage forms
Acute and subacute period
Completion of treatment
(2-4 weeks or more)
Basic BMR in case of inflammation (CRP level 3-7 mg/l) 
Traumeel S 2,2 ml (1 amp) i/m, s/c, i/c daily No 3-5 2,2 ml (1 amp) i/m, s/c, i/c 2-3  times (up to decrease of CRP below 
3 mg / l)
Ointment: easily to rub in/ apply under the bandage / 
apply on the affected area: on the 1st day – 5-6 times, 
then 3 times / day 
Ointment: easily to rub in/ apply 2-3 times / day, incl. with mas-
sage or injected with phonophoresis No 10 (daily)
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Conclusions
The complex bioregulatory action of the medicine Trau-
meel S allows to control and optimize the course of the in-
flammatory process wherever it is located and of any form. Its 
use contributes to the full completion of inflammation with 
the recovery of the structure and function of the tissue, reduc-
es the risk of complications and chronic inflammation. Such 
characteristics, combined with good tolerability (absence 
of side effects characteristic to NSAIDs) make Traumeel S a 
simple and reliable assistant to a doctor of any specialty in the 
treatment of inflammatory diseases of different localization.
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